ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 12,500 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $16.00, for a total value of $200,000.00. Following the completion of the transaction, the chief financial officer now directly owns 4,949 shares in the company, valued at $79,184. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

ARS Pharmaceuticals Stock Down 2.4 %

Shares of NASDAQ SPRY opened at $16.13 on Friday. The business has a fifty day simple moving average of $13.51 and a two-hundred day simple moving average of $10.76. ARS Pharmaceuticals, Inc. has a twelve month low of $3.35 and a twelve month high of $16.89.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $2.00 million. As a group, sell-side analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on SPRY. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Leerink Partners lifted their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Finally, William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $24.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in ARS Pharmaceuticals by 37.0% during the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock worth $29,500,000 after buying an additional 779,969 shares during the last quarter. ClariVest Asset Management LLC purchased a new stake in ARS Pharmaceuticals during the 1st quarter valued at about $2,790,000. SG Americas Securities LLC grew its stake in ARS Pharmaceuticals by 861.5% during the 2nd quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock valued at $950,000 after purchasing an additional 99,986 shares during the last quarter. GSA Capital Partners LLP grew its stake in ARS Pharmaceuticals by 11.7% during the 1st quarter. GSA Capital Partners LLP now owns 128,889 shares of the company’s stock valued at $1,317,000 after purchasing an additional 13,545 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in ARS Pharmaceuticals by 99.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,285 shares of the company’s stock valued at $1,185,000 after purchasing an additional 69,394 shares during the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.